TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: cardiopulmonary alterations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: coagulation, fibrinolytic and cytokine response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pharmacokinetic profile of linifanib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Cytokine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mineral metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUCt of CKD-320
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of CKD-320
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline OA Pain in the Target Knee as Assessed by the Weekly Average of Daily Pain Numeric Rating Scale (NRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline OA Pain in the Target Knee as Assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscore (WOMAC Pain)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline OA Function in the Target Knee as Assessed by WOMAC Physical Function Subscore (WOMAC Function)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically relevant post operative pancreatic fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in functional Magnetic Resonance Imaging blood oxygen-dependent signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in diffusion tensor imaging measured change in fractional anisotropy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Safety and tolerability of CR011-vcMMAE
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose (MTD) of CR011-vcMMAE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maximum Trough Concentration (Ctrough) of Daratumumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of School Teacher Behaviors
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Glycemic Control (hemoglobin A1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mandibular opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T/B Ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: imaging parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Reporting Patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with Grade 3 or more toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence, severity and dose-relationship of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Match rate of PD-L1 protein expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in C-peptide ln(AUC+1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incidence of serious adverse events, especially secondary malignant tumors
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients Starting First-Line Therapy with CDKi 4/6
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cmax of Methyldopa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of Methyldopa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of corneal stromal infiltrate(s)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with PD-L1 positive
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: COVID-19 Seroconversion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction of initial LVOT gradient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum tolerated dose of bortezomib
Endpoint domain: Adverse events/effects
Primary endpoint: Heart failure related hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Unified Parkinson's Disease Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Tremor Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Motor dysfunction measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Comfort scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Metacognitive performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predecisional behavioral variables
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: EEG markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death (all cause)
Endpoint domain: Mortality/survival
Primary endpoint: Illness perception for schizophrenia
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in child mental health scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time taken to insert rectus sheath catheters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Relapse into clinical HE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Humoral rejection diagnosed by biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: number of missed adenomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Child Sleep Quality
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in Pirani Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of clinically relevant DGE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: diagnostic value of heart type fatty acid binding protein testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Structural changes in brain structures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: BOLD changes in brain structures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: infant development level
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Referral to cardiology clinic
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Fecal Clostridium difficile numbers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Progression-Free Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of PSD502 application
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of significant upper GI findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Efficacy of GV550
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of recovery 40 (QoR-40)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in healthcare professionals' communication style
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Tc-99 MDP uptake in bone metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of patients achieving diabetes resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum tolerated dose of Toca 511
Endpoint domain: Adverse events/effects
Endpoint subdomain: Any subdomain
Primary endpoint: Proliferative Vitreoretinopathy (PVR) grade CP 1 or higher
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change in Bone Densitometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline in office trough sitting diastolic blood pressure (DBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to First Rescue Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Compliance with glucose testing
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Prevention of recurrence of early stage bladder cancer
Endpoint domain: Mortality/survival
Primary endpoint: Change in Frequency of Moderate to Severe Vasomotor Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Frequency of Moderate to Severe Vasomotor Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Number of Schizophrenia-Related Hospital Admissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: intracellular advanced glycation endproducts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: hexosamine pathway
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: prostacyclin synthase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rates of testing for HIV
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Performance data from computerized Go-No Go task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychophysiological data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose (MTD) or recommended Phase II dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of combined therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of dyssynchrony
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Level of microRNA in cerebrospinal fluid and serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Progression of neuroendocrine tumor(s)
Endpoint domain: Mortality/survival
Primary endpoint: Immune-related Clinical Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Response time for avoidance and affordance task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Varenicline area under the curve (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Varenicline area under the curve (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in blood and parenteral iron requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Assessment of arm/hand function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of attempts to place the venous catheter for venipuncture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Occurrence of solicited local and systemic reactogenicity signs and symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of serious adverse events and incident chronic medical conditions
Endpoint domain: Adverse events/effects
Primary endpoint: Clearance variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of distribution variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average counts of dynamic acceleration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative overcorrections and under corrections
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the size of the lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Clinical improvement in disability score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Elderly mobility scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timed Up and go test (TUG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total morphine requirements in the 24-hour postoperative period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EEG frequency spectrum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of deaths during pregnancy and up to one month after delivery
Endpoint domain: Mortality/survival
Primary endpoint: Number of neonatal deaths during pregnancy and up to one month after delivery
Endpoint domain: Mortality/survival
Primary endpoint: Annualized bleeding rate (ABR) of treated bleeding events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence and severity of thrombotic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to first resolution of delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With a Severe Asthma Exacerbation Event
Endpoint domain: Adverse events/effects
Primary endpoint: Daily mean urination frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Procalcitonine (PCT) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endometriosis symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percent of HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of patients with at least one erosion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Participants Who Develop SARS-Cov-2 Infection
Endpoint domain: Mortality/survival
Primary endpoint: Antibody Concentrations Against Pneumococcal Vaccine Serotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Effectiveness of oral montelukast in treatment of EE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-month Confirmed Disability Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma lipids assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline In The Modified Neuropathy Impairment Score (mNIS) +7 Composite Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline In The Norfolk Quality Of Life Diabetic Neuropathy (QoL-DN) Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: major pathological response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maximal change in Unified Parkinson's Disease Rating Scale (UPDRS) Part III
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in OFF time from Baseline to Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With Serious Adverse Events Related to Bevacizumab
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Radiation Therapy (RT)-Related Grade >= 4 Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of CCT301-59 CAR T cell therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of CCT301-59 CAR T cell therapy
Endpoint domain: Physiological/clinical
Primary endpoint: Kinetics of CAR T cells
Endpoint domain: Physiological/clinical
Primary endpoint: HIV-RNA Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD4 Cells Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colonic Geometric Center (GC) at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Adherence to Evidence-Based Guidelines
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Related SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Degree of COX-1 acetylation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infectivity assessed by P. falciparum DNA detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rate of graft take
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of patients reaching normal glycaemic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Cerebral Energy Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Occurrence of conjunctivitis
Endpoint domain: Adverse events/effects
Primary endpoint: Maximal Exercise Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Upper and Lower Limb Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Body Fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: knee adduction moment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Great toenail clearance or fungal clear growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in HAM-D-17 Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: sustained virologic rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protein levels of RING ubiquitin ligases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: mRNA levels of RING ubiquitin ligases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cognitive performance as measured by WRAT 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cognitive performance as measured by RAVLT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cognitive performance as measured by 3MSE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cognitive performance as measured by DSC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cognitive performance as measured by Stroop tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: POD of intra-abdominal complication detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: heart failure hospitalisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of adverse effects on the injection site
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of mortality due to lung cancer screening
Endpoint domain: Mortality/survival
Primary endpoint: Area Under the Concentration-time Curve of BI 1467335 in Plasma Over the Time Interval From 0 to 24 Hours After Administration of the First Dose (AUC0-24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Measured Concentration of BI 1467335 in Plasma After Administration of the First Dose (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve of BI 1467335 in Plasma Over the Dosing Interval After Administration of the 28th Dose (AUCτ,28)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Measured Concentration of BI 1467335 in Plasma Following Administration of the 28th Dose (Cmax,28)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of patients without recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Change in QT interval value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in QTc interval value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in transmural dispersion of repolarization (TDR) value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Anxiety levels as measured by the SCAS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of patients with complete cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Cognition due to training
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in attention and inhibitory control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Frequency and severity of Reactogenicity Events
Endpoint domain: Adverse events/effects
Primary endpoint: Causality of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Patients to Experience at Least One Treatment-emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Ratio of subjects with 25 OHD concentration < 15 ng/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pixel gradient of the thermal wound surface
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes